[go: up one dir, main page]

AU2001236519A1 - Identification, assessment, prevention, and therapy of prostate cancer - Google Patents

Identification, assessment, prevention, and therapy of prostate cancer

Info

Publication number
AU2001236519A1
AU2001236519A1 AU2001236519A AU3651901A AU2001236519A1 AU 2001236519 A1 AU2001236519 A1 AU 2001236519A1 AU 2001236519 A AU2001236519 A AU 2001236519A AU 3651901 A AU3651901 A AU 3651901A AU 2001236519 A1 AU2001236519 A1 AU 2001236519A1
Authority
AU
Australia
Prior art keywords
assessment
therapy
prevention
identification
prostate cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001236519A
Inventor
Wilson Endege
John E. Monahan
Robert Schlegel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
MILLENNIUM PREDICTIVE MEDICINE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MILLENNIUM PREDICTIVE MEDICINE filed Critical MILLENNIUM PREDICTIVE MEDICINE
Publication of AU2001236519A1 publication Critical patent/AU2001236519A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G01N33/57555—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
AU2001236519A 2000-01-24 2001-01-24 Identification, assessment, prevention, and therapy of prostate cancer Abandoned AU2001236519A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US17852500P 2000-01-24 2000-01-24
US60/178,525 2000-01-24
US18324500P 2000-02-17 2000-02-17
US60/183,245 2000-02-17
US19013900P 2000-03-16 2000-03-16
US60/190,139 2000-03-16
US20812600P 2000-05-31 2000-05-31
US60/208,126 2000-05-31
US21970500P 2000-07-18 2000-07-18
US60/219,705 2000-07-18
US25516000P 2000-12-13 2000-12-13
US60/255,160 2000-12-13
PCT/US2001/002318 WO2001053836A2 (en) 2000-01-24 2001-01-24 Identification, assessment, prevention, and therapy of prostate cancer

Publications (1)

Publication Number Publication Date
AU2001236519A1 true AU2001236519A1 (en) 2001-07-31

Family

ID=27558680

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001236519A Abandoned AU2001236519A1 (en) 2000-01-24 2001-01-24 Identification, assessment, prevention, and therapy of prostate cancer

Country Status (3)

Country Link
US (1) US20020168638A1 (en)
AU (1) AU2001236519A1 (en)
WO (1) WO2001053836A2 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329505B1 (en) 1997-02-25 2001-12-11 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
ES2402947T3 (en) * 1997-04-10 2013-05-10 Stichting Katholieke Universiteit University Medical Centre Nijmegen PCA3, PCA3 genes and methods of use
US20080050836A1 (en) * 1998-05-01 2008-02-28 Isabelle Guyon Biomarkers for screening, predicting, and monitoring benign prostate hyperplasia
DK2182064T3 (en) 1998-09-30 2012-12-17 Agensys Inc Gene expressed in prostate cancer
US6943235B1 (en) 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
DE60027027T2 (en) 1999-09-29 2006-11-30 Diagnocure Inc. PCA3 MRNA IN GOOD AND MASTILE PROSTATE WEAVE
JP2004510442A (en) * 2000-10-03 2004-04-08 グラクソ　グループ　リミテッド Tumor markers and methods of use
US20090226915A1 (en) 2001-01-24 2009-09-10 Health Discovery Corporation Methods for Screening, Predicting and Monitoring Prostate Cancer
WO2003060145A2 (en) * 2001-12-21 2003-07-24 Diadexus, Inc. Compositions and methods relating to pancreatic specific genes and proteins
US8008012B2 (en) 2002-01-24 2011-08-30 Health Discovery Corporation Biomarkers downregulated in prostate cancer
WO2003074725A2 (en) * 2002-03-01 2003-09-12 Exelixis, Inc. MBCATs AS MODIFIERS OF THE BETA-CATENIN PATHWAY AND METHODS OF USE
WO2003087154A2 (en) * 2002-04-12 2003-10-23 Molecular Engines Laboratories Sequences involved in the phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses, and the use of the same as medicaments
WO2003087122A2 (en) * 2002-04-12 2003-10-23 Molecular Engines Laboratories Sequences involved in the phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses, and the use of the same as medicaments
AU2003298689A1 (en) * 2002-11-21 2004-06-18 Wyeth Methods for diagnosing rcc and other solid tumors
PL400309A1 (en) 2002-12-23 2013-10-14 Immunex Corporation Nucleic acids, proteins and BTL-II antibodies
WO2004070056A2 (en) * 2003-02-07 2004-08-19 Diagnocure Inc. Method to detect prostate cancer in a sample
US7643943B2 (en) 2003-02-11 2010-01-05 Wyeth Llc Methods for monitoring drug activities in vivo
US20060194211A1 (en) * 2003-04-29 2006-08-31 Burczynski Michael E Methods for prognosis and treatment of solid tumors
US11105808B2 (en) 2004-11-12 2021-08-31 Health Discovery Corporation Methods for screening, predicting and monitoring prostate cancer
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
US20070037186A1 (en) 2005-05-20 2007-02-15 Yuqiu Jiang Thyroid fine needle aspiration molecular assay
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
CA2622295C (en) 2005-09-12 2019-01-15 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US8841266B2 (en) * 2005-11-17 2014-09-23 Tel Hashomer Medical Research Infrastructure And Services Ltd. Pharmaceutical composition and method for regulating abnormal cellular proliferation
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
AU2008275303B2 (en) 2007-07-06 2012-05-03 The Regents Of The University Of Michigan MIPOL1-ETV1 gene rearrangements
US8106037B2 (en) 2007-08-03 2012-01-31 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
WO2009143603A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
WO2011034906A2 (en) 2009-09-17 2011-03-24 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
US9241850B2 (en) 2011-09-02 2016-01-26 Ferno-Washington, Inc. Litter support assembly for medical care units having a shock load absorber and methods of their use
US10513737B2 (en) 2011-12-13 2019-12-24 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
EP3435084B1 (en) 2012-08-16 2023-02-22 Decipher Biosciences, Inc. Prostate cancer prognostics using biomarkers
US20150252425A1 (en) * 2014-03-05 2015-09-10 Caldera Health Ltd. Gene expression profiling for the diagnosis of prostate cancer
CN110506127B (en) 2016-08-24 2024-01-12 维拉科特Sd公司 Use of genomic signatures to predict responsiveness to postoperative radiotherapy in prostate cancer patients
JP2020502218A (en) 2016-12-21 2020-01-23 メレオ バイオファーマ ３ リミテッド Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
WO2018132916A1 (en) 2017-01-20 2018-07-26 Genomedx Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
EP3593140A4 (en) 2017-03-09 2021-01-06 Decipher Biosciences, Inc. PROSTATE CANCER SUB-TYPING TO PREDICT RESPONSE TO HORMONAL THERAPY
AU2018266733A1 (en) 2017-05-12 2020-01-16 Veracyte, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
WO2019028285A2 (en) 2017-08-04 2019-02-07 Genomedx, Inc. Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy
CN108866191B (en) * 2018-07-26 2021-07-09 上海奕谱生物科技有限公司 Methylation-based tumor marker STAMP-EP2
CN117568475B (en) * 2023-01-04 2025-02-25 唐山市人民医院 ICON probe, detection kit and application of human LINE transposon DNA methylation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1047793B1 (en) * 1998-01-21 2006-11-15 Dianon Systems, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6476207B1 (en) * 1998-06-11 2002-11-05 Chiron Corporation Genes and gene expression products that are differentially regulated in prostate cancer
CA2381319A1 (en) * 1999-06-01 2000-12-07 Incyte Genomics, Inc. Molecules for diagnostics and therapeutics

Also Published As

Publication number Publication date
WO2001053836A3 (en) 2002-06-06
WO2001053836A9 (en) 2002-11-07
WO2001053836A2 (en) 2001-07-26
US20020168638A1 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
AU2001236519A1 (en) Identification, assessment, prevention, and therapy of prostate cancer
AU2001241541A1 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
AU2002337657A1 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
AU2002322280A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2074201A (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
AU2001251613A1 (en) Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
AUPQ923100A0 (en) Treatment of prostate cancer
AU2001245295A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
AU2001268467A1 (en) Identification of genes and compounds for treatment of cancer
MXPA03008582A (en) Agents and methods for treatment of cancer.
AU2001266838A1 (en) Inhibitors of matriptase for the treatment of cancer
AU2074101A (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
AU2596901A (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2002313426A1 (en) Tumor antigens for prevention and/or treatment of cancer
AU2001238493A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
AU2001241779A1 (en) Method of treatment of prostate cancer
AU2002330724A1 (en) Diagnosis, prevention and treatment of cancer
AU2002211359A1 (en) Stem cell-based methods for preventing and treating tumor
AU2001297571A1 (en) Detection and treatment of prostate cancer
AU2001245939A1 (en) Compositions and methods for the identification, assessment, prevention, and therapy of human cancers
IL132531A0 (en) Detection and therapy of tumors
AU2001259160A1 (en) Compositions and methods for the identification, assessment, prevention, and therapy of human cancers
AU2003231912A1 (en) Methods of detecting and treating prostate cancer
AU2001291256A1 (en) Methods and compositions for the identification, assessment and therapy of human cancers